The Appointment of Clay Siegall to the Board of Mira Therapeutics

Mirna Therapeutics is a biotechnology-based firm. In January 2013, the company announced that Seattle Genetics would be appointed to the member of the board of council as an outside director. Clay Siegall is the co-founder of Seattle Genetics. He is the current chief executive and chairperson of the board of trustees of Seattle Genetics.

Mirna Therapeutics is based in Austin, Texas and was established in 2007. The firm focuses on microRNA in therapeutics. Currently, the company is focused on cancer research. Dr. Siegall has a background in cancer research, and that explains why he was appointed to the board of directors. Dr. Paul Lammers is the chief executive officer and president of Mira. Dr. Paul said that the company was excited to be associated with an expert who has experience in cancer research. Dr. Paul further explained that he expects Dr. Siegall to guide the company towards developing their microRNA-based therapeutics.

Mirna has a portfolio containing more than 300 miRNAs with applications in various diseases like oncology. It has foundational intellectual property collection on the therapeutic use of miRNAs. Oncology-directed miRNAs have proven to block the growth of tumor in different re-clinical animal studies. The firm has received funding from the state of Texas and private investors.

About Clay Siegall
Before founding Seattle Genetics, Dr. Siegall was working with Bristol-Myers Squibb Pharmaceutical Research Institute. He worked at the Institute from 1991 to 1997. Dr. Siegall also worked with the National Cancer Institute from 1988 to 1991 and National Institutes of Health. Dr. Siegall is on the board of directors of Alder BioPharmaceuticals, a private firm. He is also a member of the Council of Washington Biotechnology and Biomedical Association (WBBA). Dr. Siegall received a Ph.D. in Genetics from George Washington University. He also holds a B.S. in zoology from the University of Maryland.

Seattle Genetic is a biotechnology firm that deals with developing preclinical and clinical products. The biotech firm was formed in 1998. Over the years, the company has commercialized and developed innovative antibody-drug conjugate (ADC) for treating cancer. ADC is a technology that reduces toxic effects of chemotherapy and improves antitumor activity. The firm’s headquarters are in Bothell Washington. It trades on Nasdaq Stock Market.

Leave a Reply